Biochemical and molecular-genetic indicators of inflammation and apoptosis in liver cirrhosis as an outcome of the progression of non-alcoholic steatohepatitis


Cite item

Full Text

Abstract

Aim. A comparative analysis of the complex of clinical and laboratory indicators (including the content of cytokines in blood plasma and the level of expression of TNF and IL6 genes in peripheral leukocytes, as well as the level of biochemical and molecular-genetic indicators of apoptosis, such as the content of tissue polypeptide-specific antigen (TPS) in the blood, the activity of caspases 3, 8 and 9 and the expression level of the encoding genes in peripheral blood leukocytes) in patients with non-alcoholic fatty liver disease (NAFLD) with non-alcoholic steatohepatitis (NASH) of different activity, liver cirrhosis (LC) classes A and B and in the donors of control group. Materials and methods. 158 patients with NAFLD were examined: 116 patients with NASH diagnosed for the first time (NASH of weak, moderate and high activity) and 42 patients with the NAFLD at the stage of liver cirrhosis diagnosed for the first time (classes A and B according to the Child-Pugh classification). The control group consisted of 54 healthy donors. The clinical blood biochemistry, cytokine profile, tissue polypeptide-specific antigen content, the level of the TNF, IL6 gene and caspase gene transcription as well as caspase activity in peripheral blood leukocytes (PBL) were evaluated. Results and discussion. In the progression of NASH to LC, together with changes in general clinical parameters, the cytokine profile are changed due to an increase in the level of IL-6 and IL-1β; in peripheral leukocytes, the activity of caspase 9 increases and the activity of caspase 8 decreases compared to NASH, and the level of the TNF gene expression decreases as compared to NASH of high activity. These parameters can be considered as promising minimally invasive markers of progression of NAFLD to LC. Conclusion. In nonalcoholic cirrhosis as an outcome of the progression of non-alcoholic steatohepatitis changes in clinical parameters (indicating the development of hepatocellular deficiency, violation of protein and lipid metabolism, progressive inflammation) are accompanied by specific changes in levels of biochemical and molecular-genetic indicators of apoptosis and inflammation. With the progression of NASH to LC, the cytokine profile changes due to an increase in the level of proinflammatory cytokines, the apoptosis processes triggered by the internal pathway increase and the activity of apoptosis activated via the external pathway decreases in PBL

About the authors

I V Kurbatova

Institute of Biology of the Karelian Research Centre of the Russian Academy of Sciences (IB KarRC RAS), Laboratory for Genetics

Email: irina7m@yandex.ru
к.б.н., н.с. лаб. генетики Института биологии КарНЦ РАН; тел.: +7(8142)57; ORCID: 0000-0001-7620-7065 Petrozavodsk, Russia

L V Topchieva

Institute of Biology of the Karelian Research Centre of the Russian Academy of Sciences (IB KarRC RAS), Laboratory for Genetics

к.б.н., в.н.с. лаб. генетики Института биологии КарНЦ РАН Petrozavodsk, Russia

O P Dudanova

Petrozavodsk State University, Institute of Medicine, Department of Propaedeutics of Internal Diseases and Hygiene

д.м.н., проф., зав. каф. пропедевтики внутренних болезней и гигиены Медицинского института ФГБОУ ВО «ПетрГУ» Petrozavodsk, Russia

A A Shipovskaya

Petrozavodsk State University, Institute of Medicine, Department of Propaedeutics of Internal Diseases and Hygiene

аспирант каф. пропедевтики внутренних болезней и гигиены Медицинского института ФГБОУ ВО «ПетрГУ» Petrozavodsk, Russia

References

  1. Adams L.A, Ratziu V. Non - alcoholic fatty liver - perhaps not so benign. J Hepatol. 2015;62(5):1002-4. doi: 10.1016/j.jhep.2015.02.005
  2. Liu B, Balkwill A, Reeves G, Beral V; Million Women Study Collaborators. Body mass index and risk of liver cirrhosis in middle aged UK women: prospective study. BMJ. 2010;340:с912. doi: 10.1136/bmj.c912
  3. Ивашкин В.Т., Маевская М.В. Лечение осложнений цирроза печени: методические рекомендации для врачей. М.: Литтерра; 2011.
  4. Ивашкин В.Т., Маевская М.В., Павлов Ч.С., Федосьина Е.А., Бессонова Е.Н., Пирогова И.Ю., Гарбузенко Д.В. Клинические рекомендации Российского общества по изучению печени и Российской гастроэнтерологической ассоциации по лечению осложнений цирроза печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;26(4):71-102. doi: 10.22416/1382-4376-2016-4-71-102
  5. Дуданова О.П., Шиповская А.А., Курбатова И.В., Ларина Н.А. Неалкогольная жировая болезнь печени: патогенез, клинические проявления, методы диагностики и лечения. Петрозаводск: Изд - во ПетрГУ; 2017.
  6. Курбатова И.В., Дуданова О.П. Особенности некротически - воспалительного процесса при разных формах неалкогольной жировой болезни печени. Терапевтический архив. 2017;89(2):52-8. doi: 10.17116/terarkh201789252-58
  7. Brunt E.M, Janney C.G, Diisceglie A.M, Neuschwander-Tetri B.A, Bacon B.R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94(9):2467-74. doi: 10.1111/j.1572-0241.1999.01377.x
  8. Child C.G, Turcotte J.G. Surgery and portal hypertension. Major Probl Clin Surg. 1964;1:1-85.
  9. Pugh R.N, Murray-Lyon I.M, Dawson J.L, Pietroni M.C, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Brit J Surg. 1973;60(8):646-9. doi: 10.1002/bjs.1800600817
  10. Livak K.J, Schmittgen T.D. Analysis of relative gene expression data using Real-Time quantitative PCR and the 2-∆∆CT method. Methods. 2001;25(4):402-8. doi: 10.1006/meth.2001.1262
  11. Pinto J.P, Dias V, Zoller H, Porto G, Carmo H, Carvalho F, de Sousa M. Hepcidin messenger RNA expression in human lymphocytes. Immunology. 2010;130(2):217-30. doi: 10.1111/j.1365-2567.2009.03226.x
  12. Wang F, Xu L, Feng X, Guo D, Tan W, Zhang M. Interleukin-29 modulates proinflammatory cytokine production in synovial inflammation of rheumatoid arthritis. Arthritis Res Ther. 2012;14(5):R228. doi: 10.1186/ar4067
  13. Braunersreuther V, Viviani G.L, Mach F, Montecucco F. Role of cytokines and chemokines in non - alcoholic fatty liver disease. World J Gastroenterol. 2012;18(8):727-35. doi: 10.3748/wjg.v18.i8.727
  14. Neuman M.G, Cohen L.B, Nanau R.M. Biomarkers in nonalcoholic fatty liver disease. Can J Gastroenterol Hepatol. 2014;28(11):607-18. doi: 10.1155/2014/757929
  15. Yilmaz Y. Systematic review: caspasecleaved fragments of cytokeratin 18 (the promises and challenges of a biomarker for chronic liver disease. Aliment Pharmacol Ther. 2009;30(11-12):1103-9. doi: 10.1111/j.1365-2036.2009.04148.x
  16. Singh S, Allen A.M, Wang Z, Prokop L.J, Murad M.H, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta - analysis of paired - biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643-54. doi: 10.1016/j.cgh.2014.04.014
  17. Kawanaka M, Nishino K, Nakamura J, Urata N, Oka T, Goto D, Suehiro M, Kawamoto H, Yamada G. Correlation between serum cytokeratin-18 and the progression or regression of non - alcoholic fatty liver disease. Ann Hepatol. 2015;14(6):837-44. doi: 10.5604/16652681.1171767
  18. Ribeiro P.S, Cortez-Pinto H, Solá S, Castro R.E, Ramalho R.M, Baptista A, Moura M.C, Camilo M.E, Rodrigues C.M. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Amer J Gastroenterol. 2004;99(9):1708-17. doi: 10.1111/j.1572-0241.2004.40009.x
  19. Guicciardi M.E, Gores G.J. Apoptosis as a mechanism for liver disease progression. Semiт Liver Dis. 2010;30(4):402-10. doi: 10.1055/s-0030-1267540
  20. Буеверов А.О., Киселева О.Ю., Ивашкин В.Т., Белушкина Н.Н., Москалева Е.Ю., Широкова Е.Н., Маевская М.В. Сравнительная характеристика апоптоза периферических лейкоцитов при вирусных и аутоиммунных заболеваниях печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2009;(4):41-7.
  21. Shi Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell. 2002;9(3):459-70. doi: 10.1016/s1097-2765(02)00482-3
  22. Hengartner M.O. The biochemistry of apoptosis. Nature. 2000;407(6805):770-6. doi: 10.1038/35037710
  23. Jayakumar S, Harrison S.A, Loomba R. Noninvasive markers of fibrosis and inflammation in nonalcoholic fatty liver disease. Curr Hepatol Rep. 2016;15(2):86-95. doi: 10.1007/s11901-016-0296-8

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies